ASPREE PI editorial in this week’s ‘Medical Observer’
ASPREE Principal Investigator in Australia, Professor John McNeil discusses what the findings of ASPREE trial may mean to future health care.
“Currently, it is not known if low-grade inflammation is a cause or consequence of the diseases of ageing. If ASPREE shows lower incidence of disease and disability among those with reduced inflammatory markers, it will suggest inflammation as a potential cause of these conditions. This will be a key finding and may lead to the prophylactic use of anti-inflammatory agents in older people,“ writes Prof McNeil.
Read the full article here.
ASPREE would like to sincerely thank the Jean Hailes Foundation for facilitating this article and for their support for this very important study.